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■  C L I N I C A L  S C I E N C E  ■
Evaluation of Abicipar Pegol (an Anti-VEGF 
DARPin Therapeutic) in Patients With Neovascular 
Age-Related Macular Degeneration: Studies in 
Japan and the United States
Derek Kunimoto, MD, JD; Masahito Ohji, MD; Raj K. Maturi, MD; Tetsuju Sekiryu, MD;  
Ying Wang, MD, PhD; Grace Pan, MS; Xiao-Yan Li, MD; Susan Schneider, MD; for the BAMBOO and 
CYPRESS Study Groups
BACKGROUND AND OBJECTIVE: To evaluate compa-
rability of abicipar pegol (abicipar) effects in pa-
tients with treatment-naïve neovascular age-related 
macular degeneration (nAMD) in Japan and the 
United States.
PATIENTS AND METHODS: Phase 2, multicenter, 
randomized, double-masked, 20-week studies 
(BAMBOO, Japan; CYPRESS, United States). Pa-
tients (n = 25 each study) received three monthly 
intravitreal injections of abicipar 1 mg or 2 mg 
or five monthly intravitreal injections of ranibi-
zumab 0.5 mg.
RESULTS: Mean best-corrected visual acuity change 
from baseline at week 16 (primary endpoint) for 
abicipar 1 mg, abicipar 2 mg, and ranibizumab 
was +7.8 letters, +8.9 letters, and +17.4 letters 
(BAMBOO); +4.4 letters, +10.1 letters, and +15.2 
letters (CYPRESS). Mean central retinal thickness 
change from baseline was −187.3 μm, −196.5 μm, 
and −230.4 μm (BAMBOO); −106.5 μm, −112.8 
μm, and −124.4 μm (CYPRESS). Uveitis or vitritis 
was reported in three abicipar-treated patients.
CONCLUSION: Abicipar demonstrated extended 
duration of effect and safety that were comparable 
between Japanese and non-Japanese patients with 
nAMD. Abicipar effectively treated Japanese pa-
tients with polypoidal choroidal vasculopathy.
[Ophthalmic Surg Lasers Imaging Retina. 2019;50:e10-e22.]
INTRODUCTION
Age-related macular degeneration (AMD), the 
leading cause of blindness in individuals 65 years of 
age and older in the developed world, is a progressive 
degeneration of the retinal pigment epithelium (RPE) 
and photoreceptors.1 Neovascular AMD (nAMD) is an 
advanced stage of the disease characterized by cho-
roidal neovascularization (CNV). In nAMD, newly 
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formed immature blood vessels originating in the 
choroid grow into the space beneath the neurosen-
sory retina or RPE, and the vessel growth and exuda-
tion cause tissue disruption, subretinal disciform scar 
formation, and degeneration of the overlying neuro-
sensory retina.1
Intravitreal injections of vascular endothelial 
growth factor (VEGF) blockers including ranibi-
zumab (Lucentis; Genentech, South San Francisco, 
CA), bevacizumab (Avastin; Genentech, South San 
Francisco, CA), aflibercept (Eylea; Regeneron, Tar-
rytown, NY), and pegaptanib (Macugen; Bausch + 
Lomb, Rochester, NY), which can inhibit CNV lesion 
growth and exudation and stabilize or improve vi-
sual acuity (VA) in many patients,2 are currently the 
mainstay of treatment for nAMD. However, frequent 
injections are required for sustained efficacy. Data 
from large, prospective studies of ranibizumab ad-
ministered monthly (ANCHOR3 and MARINA4) or as 
needed (SUSTAIN5 and HORIZON6) in patients with 
nAMD have suggested that outcomes are better with 
intensive, monthly dosing of ranibizumab. More-
over, subtypes of nAMD that have been identified 
(typical nAMD, polypoidal choroidal vasculopathy 
[PCV], and retinal angiomatous proliferation) appear 
to differ in their responsiveness to anti-VEGF treat-
ment.7-9 In a cross-sectional, retrospective study, most 
patients diagnosed with nAMD who demonstrated a 
poor response to ranibizumab had atypical nAMD, 
with the majority having PCV.10 These results suggest 
a need for novel treatments for nAMD that require 
less-frequent administration (decreasing the burden 
of treatment) and that are effective in atypical sub-
types of nAMD lesions.
Abicipar pegol (abicipar; Allergan, Dublin, Ire-
land), a member of the family of DARPin therapeu-
tics (Molecular Partners, Zurich, Switzerland), is a 
pegylated 34 kDa recombinant ankyrin repeat protein 
that binds all isoforms of VEGF-A with high affinity 
and specificity.11-13 Abicipar binds to VEGF-A165 with 
higher affinity than ranibizumab (Kd of 2 pM13 ver-
sus 46 pM14) and has demonstrated potent inhibition 
of anti-VEGF activity (IC50 of 17 pM) in a spheroid 
sprouting assay.11 Studies of aqueous humor concen-
trations of anti-VEGF agents after intravitreal admin-
istration in human subjects have reported a longer 
intraocular half-life for abicipar (≥ 13 days) compared 
with 7.2 days for ranibizumab,15 with abicipar pres-
ent at concentrations orders of magnitude above the 
IC50 for VEGF inhibition for at least 12 weeks after 
intravitreal administration of a 0.4-mg dose.11
These findings suggest that abicipar may dem-
onstrate a longer duration of effect compared with 
ranibizumab, and that the required frequency of in-
travitreal injections may be markedly reduced. Ab-
icipar is currently under evaluation as a long-acting 
intravitreal anti-VEGF therapy for nAMD. In stage 3 
of the phase 2 REACH study (NCT01397409), abicipar 
1 mg and 2 mg improved best-corrected VA (BCVA) 
and central retinal thickness (CRT; retinal thickness 
in the 1 mm diameter central subfield) similarly to 
ranibizumab 0.5 mg, but with a reduced number of 
injections.16
In this report, we present the results of two ad-
ditional small, exploratory, phase 2 clinical studies 
(BAMBOO; CYPRESS) assessing the safety and ef-
ficacy of abicipar 1 mg and 2 mg in Japan and the 
United States, respectively. Ranibizumab 0.5 mg was 
also used in these studies as an active control. Our 
study objective was to evaluate the comparability 
of abicipar effects in Japanese and non-Japanese pa-
tients with nAMD. Accordingly, the clinical studies 
were nearly identical in design, such that regulatory 
requirements of the Pharmaceuticals and Medical De-
vice Agency in Japan could be met.
PATIENTS AND METHODS
Two phase 2, multicenter, randomized, double-
masked clinical studies evaluated the safety and 
treatment effects of abicipar 1 mg, abicipar 2 mg, and 
ranibizumab 0.5 mg in treatment-naïve patients with 
nAMD in Japan (BAMBOO study) and the United 
States (CYPRESS study). The studies were conducted 
from September 2014 to December 2015 (BAMBOO) 
and July 2014 to March 2015 (CYPRESS) in accor-
dance with the International Council for Harmoni-
zation Good Clinical Practice Guideline. The study 
protocol was approved by an institutional review 
board at each site, and all patients provided written 
informed consent.
Patient Selection
Patient inclusion criteria included active subfo-
veal and/or juxtafoveal CNV secondary to AMD in 
the study eye, with retinal fluid and/or leakage af-
fecting the fovea, diagnosed within the 12 months 
before screening. Active CNV was determined by 
the presence of retinal fluid on spectral-domain op-
tical coherence tomography (SD-OCT) as confirmed 
by the central reading center (University of Wiscon-
sin Fundus Photography Reading Center, Madison, 
Wisconsin), with CRT in the study eye greater than 
320 μm on the Spectralis machine (Heidelberg En-
gineering, Heidelberg, Germany) or greater than 300 
μm on the Cirrus machine (Carl Zeiss Meditec, Jena, 
Germany). Other key inclusion criteria included CNV 
lesion area greater than 50% of the total lesion area 
and not larger than 12 disc areas on fluorescein angi-
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ography in the study eye, and BCVA between 24 and 
75 Early Treatment Diabetic Retinopathy Study (ET-
DRS) letters (approximately 20/32 to 20/320 Snellen 
equivalent) in the study eye and 34 or more ETDRS 
letters (approximately 20/200 or better) in the fellow 
eye. Patients were required to be at least 50 years of 
age, and those in the BAMBOO study were required 
to be of Japanese descent. Inclusion was limited to 
patients who had not received any previously ad-
ministered therapy (verteporfin [Visudyne; Bausch + 
Lomb, Rochester, NY] or anti-angiogenic therapy, ap-
proved or investigational) for nAMD in the study eye. 
The BAMBOO study included indocyanine green 
angiography (ICGA) at screening because of the high 
prevalence of PCV in Japanese patients with nAMD.17 
Patients with or without PCV could be included in 
the study.
Exclusion criteria for study eyes included presence 
Figure 1. Study design schematic. Additional safety study visits were scheduled 2 days after the baseline and week 8 visits. B = baseline.
Figure 2. Mean change from baseline in best-corrected visual acuity (BCVA) at each visit in the BAMBOO and CYPRESS studies. The 
primary endpoint was at week 16. Green and orange arrows indicate treatment with abicipar and ranibizumab, respectively. Missing data 
were imputed with the last observation carried forward. Errors bars indicate standard error of the mean.
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of a retinal angiomatous proliferation lesion, structur-
al damage to the center of the macula likely to pre-
clude improvement in BCVA (eg, subretinal fibrosis/
scarring), vitreous hemorrhage, macular hemorrhage 
greater than 50% of the lesion area or greater than 1 
disc area in size involving the center of fovea, history 
of vitrectomy or submacular surgery, history of treat-
ment with fluocinolone acetonide implant within the 
past 36 months or with other ocular corticosteroid in-
jections within the past 6 months, and high myopia 
Figure 3. Percentage of patients who gained at least 10 letters in best-corrected visual acuity (BCVA) from baseline at each visit in the 
BAMBOO and CYPRESS studies. Green and orange arrows indicate treatment with abicipar and ranibizumab, respectively. Missing data 
were imputed with the last observation carried forward.
Figure 4. Mean change from baseline in central retinal thickness (CRT) at each visit in the BAMBOO and CYPRESS studies. Green and 
orange arrows indicate treatment with abicipar and ranibizumab, respectively. Missing data were imputed with the last observation carried 
forward. Errors bars indicate standard error of the mean.
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(≤ −6 diopters spherical equivalent). Other key exclu-
sion criteria included history of recurrent or active 
systemic or ocular / intraocular infection or inflam-
mation, and any systemic or ophthalmic medical con-
dition that in the opinion of the investigator could 
prevent safe participation in the study and adherence 
to the study visits, or that could confound the study 
results.
If both eyes met the eligibility criteria, the eye 
with the worse BCVA was selected as the study eye.
Randomization and Study Treatment
Each study included a screening visit (day −21 to 
day −2); a baseline visit (day 1); and visits at weeks 
1, 4, 8, 12, 16, and 20. In addition, patients were seen 
at visits 2 days after the baseline and week 8 visits 
for pharmacokinetic blood sampling and safety as-
sessments only. At the baseline visit, 25 patients in 
each study were randomly assigned in a 2:2:1 ratio 
to treatment with abicipar 1 mg (n = 10), abicipar 2 
mg (n = 10), and ranibizumab 0.5 mg (n = 5) in the 
study eye. Ranibizumab was administered by intra-
vitreal injection of 50 μL of a 10 mg/mL solution at 
baseline and every 4 weeks through week 16 (a total 
of five monthly injections). In the abicipar treatment 
arms, abicipar was administered by intravitreal injec-
tion of 50 μL of a 20 mg/mL or 40 mg/mL solution at 
baseline, week 4, and week 8 (a total of three monthly 
injections), and a sham procedure was performed at 
weeks 12 and 16 to maintain masking (Figure 1). Pa-
tients, the investigator responsible for safety assess-
ments (except the post-injection assessment), and all 
site personnel involved in efficacy assessments were 
masked to patients’ treatment assignments. The oph-
thalmologist who performed the study drug injec-
tions was unmasked to the treatment.
Figure 5. Spectral-domain optical coherence tomography images and best-corrected visual acuity (BCVA) in a 91-year-old Caucasian 
female with neovascular age-related macular degeneration in the right eye treated with abicipar 2 mg in the CYPRESS study. Asterisk 
indicates visit with abicipar intravitreal injection (baseline, week 4, and week 8).
February 2019 · Vol. 50, No. 2 e15
Study treatment was to be suspended if the study 
eye developed treatment-related severe intraocular 
inflammation, but it could be reinitiated at the inves-
tigator’s discretion after the inflammation resolved. 
Escape to standard-of-care (SoC) after the week 12 
visit was allowed if there was a 15-letter or greater 
decrease in BCVA compared with the worst BCVA at 
previous visits, attributable to a lack of treatment ef-
fect. Patients who escaped to SoC were to be followed 
for safety assessments through week 20.
Assessments and Outcome Measures
BCVA and CRT were assessed at baseline and at 
weeks 1, 4, 8, 12, 16, and 20. The primary efficacy 
measure was BCVA evaluated using a modification of 
the ETDRS method18 by certified, masked evaluators 
and expressed as the number of letters read. In the 
BAMBOO study, the ETDRS eye chart used Arabic 
numerals rather than Roman letters, as these are eas-
ier for Japanese patients to read. The secondary effi-
cacy measure was CRT evaluated using SD-OCT. SD-
OCT images were evaluated and CRT was quantified 
by masked readers at the central reading center. Safe-
ty measures included treatment-emergent adverse 
events (AEs) (ie, AEs with onset after the initiation of 
treatment, or ongoing AEs that increased in severity 
after the onset of treatment), BCVA, slit-lamp biomi-
croscopy, ophthalmoscopy, and intraocular pressure.
The primary endpoint was mean change from 
baseline in BCVA at week 16. Secondary endpoints 
included mean change from baseline BCVA at week 
20, proportion of patients with a 10-letter or greater 
gain in BCVA from baseline, proportion of patients 
with a 15-letter or greater gain in BCVA from base-
line, and mean change in CRT from baseline. In ad-
dition, the proportion of patients with stable vision 
Figure 6. Spectral-domain optical coherence tomography images and best-corrected visual acuity (BCVA) in a 77-year-old Japanese 
male with neovascular age-related macular degeneration and polypoidal choroidal vasculopathy in the left eye treated with abicipar 2 mg 
in the BAMBOO study. Asterisk indicates visit with abicipar intravitreal injection (baseline, week 4, and week 8).
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(defined as < 15-letter loss in BCVA from baseline) 
was evaluated at each visit.
Statistical Analysis
Efficacy outcomes in each treatment arm were 
summarized for all scheduled visits using descrip-
tive statistics in the modified intent-to-treat popu-
lation of all randomized and treated patients with 
at least one follow-up visit. Subgroup descriptive 
statistics of efficacy parameters in the BAMBOO 
study were similarly performed in patients after 
dividing them by the presence or absence of PCV 
at baseline. For all analyses, missing values were 
imputed using the last-observation-carried-forward 
method.
No statistical analysis comparing outcomes be-
tween treatment arms was planned. The planned 
sample size was 25 patients for each study (10 pa-
tients in both the abicipar 1 mg and 2 mg groups and 
five patients in the ranibizumab group). The sample 
size was determined empirically and in collaboration 
with the Pharmaceuticals and Medical Device Agen-
cy in Japan. Based on preliminary findings of BCVA 
and CRT changes in patients treated with abicipar, it 
was decided that a sample size of 10 patients in the 
abicipar 1 mg and 2 mg arms in each study would 
provide adequate data for evaluation of the compara-
bility of abicipar effects in Japanese and non-Japanese 
patients.
RESULTS
A total of 25 treatment-naïve patients with nAMD 
were enrolled in both the BAMBOO and CYPRESS 
studies. Table 1 lists baseline demographics in the 
studies. Age, gender, and race / ethnicity were similar 
across treatment arms within each study. The Japa-
TABLE 1
Baseline Patient and Lesion Characteristics
BAMBOO (Japan) CYPRESS (United States)
Characteristic Abicipar 1 mg 
(n = 10)
Abicipar 2 mg 
(n = 10)
RAN 0.5 mg 
(n = 5)
Abicipar 1 mg 
(n = 10)
Abicipar 2 mg 
(n = 10)
RAN 0.5 mg 
(n = 5)
Mean age, years 75.6 71.8 76.6 81.0 85.5 83.8
Range 64-68 63-81 65-89 66-91 71-95 74-92
Female, n (%) 1 (10) 2 (20) 1 (20) 9 (90) 7 (70) 4 (80)
Race/ethnicity, n (%)
Japanese 10 (100) 10 (100) 5 (100) 0 (0) 0 (0) 0 (0)
Caucasian 0 (0) 0 (0) 0 (0) 10 (100) 10 (100) 5 (100)
Mean BCVA, letters 54.3 58.5 55.8 55.2 59.0 57.6
Range 24-72 27-75 47-70 33-70 42-74 30-72
BCVA >70 letters 
(20/40 Snellen 
equivalent), n (%)
3 (30) 4 (40) 0 (0) 0 (0) 2 (20) 2 (40)
Mean CRT, µm 475.1 438.7 470.0 443.8 383.8 348.8
Range 296-840 288-591 363-538 285-643 278-792 313-395
Lesion type, n (%)
CNV > 50%
Predominantly 
classic
3 (30) 5 (50) 2 (40) 5 (50) 3 (30) 1 (20)
Minimally classic 1 (10) 2 (20) 3 (60) 1 (10) 1 (10) 0 (0)
Occult 6 (60) 3 (30) 0 (0) 4 (40) 5 (50) 3 (60)
CNV < 50% 0 (0)  0 (0) 0 (0) 0 (0) 1 (10) 1 (20)
PCV component, 
n (%)
5 (50) 6 (60) 3 (60) NA NA NA
BCVA = best-corrected visual acuity measured with the Early Treatment Diabetic Retinopathy Study method; CNV = choroidal neovascularization; CRT = central 
retinal thickness; NA = not available; PCV = polypoidal choroidal vasculopathy determined by indocyanine green angiography; RAN = ranibizumab
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nese patient population in BAMBOO was younger 
(mean of 74.3 years; range: 63 years to 89 years) than 
the non-Japanese patient population in CYPRESS 
(mean of 83.4 years; range: 66 years to 95 years), and 
84% of the Japanese patients were male, whereas 
80% of the non-Japanese patients were female. In 
both studies, at least 50% of patients in each treat-
ment arm had minimally classic or occult lesions in 
the study eye (Table 1).
All patients in each treatment arm completed the 
CYPRESS study. In the BAMBOO study, 22 of 25 pa-
tients completed the study. Reasons for early discon-
tinuation in BAMBOO were mild iritis/vitritis (one 
of 10 patients in the abicipar 1 mg arm), mild iritis 
(one of 10 patients in the abicipar 2 mg arm), and 
acute angle-closure glaucoma (one of five patients in 
the ranibizumab arm). No patients in either study 
escaped to SoC treatment prior to the week 20 as-
sessments.
Visual Outcomes
In both studies, analysis of mean change from base-
line in BCVA showed improvement in BCVA in each 
treatment arm at all follow-up visits (Figure 2). Mean 
(standard error of the mean [SEM]) change from base-
line in BCVA at week 16 (primary endpoint, 8 weeks af-
ter the last abicipar injection and 4 weeks after the last 
ranibizumab injection) was +7.8 (2.7) letters, +8.9 (2.9) 
letters, and +17.4 (3.6) letters in the BAMBOO study 
and +4.4 (2.8) letters, +10.1 (3.3) letters, and +15.2 
(3.0) letters in the CYPRESS study in the abicipar 1 
mg, abicipar 2 mg, and ranibizumab arms, respectively 
(Figure 2). Results of the analysis of patients with 10 
letters or 15 letters gain must be interpreted with cau-
tion because of a possible ceiling effect, since the base-
line BCVA in patients ranged up to 75 letters (Table 1). 
Nonetheless, the percentage of patients who gained at 
least 10 letters in BCVA from baseline was similar in 
the 1 mg and 2 mg abicipar arms and consistent across 
studies (eg, five of 10 [50%] with abicipar 1 mg and 2 
mg in BAMBOO and four of 10 [40%] with abicipar 
1 mg and 2 mg in CYPRESS at week 20; Figure 3). At 
week 20, 12 weeks after the last abicipar injection and 
4 weeks after the last ranibizumab injection, five of 10 
(50%), five of 10 (50%), and four of five (80%) patients 
(BAMBOO) and four of 10 (40%), four of 10 (40%), and 
three of five (60%) patients (CYPRESS) had gained at 
least 10 letters in BCVA from baseline in the abicipar 1 
mg, abicipar 2 mg, and ranibizumab arms, respectively. 
At week 20, 12 weeks after the last abicipar injection 
and 4 weeks after the last ranibizumab injection, three 
of 10 (30%), two of 10 (20%), and three of five (60%) 
patients (BAMBOO) and three of 10 (30%), three of 10 
(30%), and three of five (60%) patients (CYPRESS) had 
gained at least 15 letters in BCVA from baseline in the 
abicipar 1 mg, abicipar 2 mg, and ranibizumab arms, 
respectively.
Anatomic Outcomes
Improvements in mean change in CRT from base-
line were observed in each treatment arm at all 
follow-up visits in both the BAMBOO and CYPRESS 
TABLE 2
Efficacy Outcomes in Japanese Patients With or Without PCV (BAMBOO Study)
Patients With PCV* Patients Without PCV†
Outcome 
Measure
Abicipar 1 mg 
(n = 5)
Abicipar 2 mg 
(n = 6)
RAN 0.5 mg 
(n = 3)
Abicipar 1 mg 
(n = 5)
Abicipar 2 mg 
(n = 4)
RAN 0.5 mg 
(n = 2)
Mean (SEM) 
change from 
baseline 
BCVA at week 
16, letters
+6.0 (4.4) +9.8 (4.6) +12.3 (3.2) +9.6 (3.4) +7.5 (3.1) +25.0 (2.0)
Mean (SEM) 
change from 
baseline CRT 
at week 16, 
μm
−268.6 (69.6) −191.2 (64.1) −253.7 (10.1) −106.0 (37.4) −204.5 (35.5) −195.5 (68.5)
Missing data were imputed with the last observation carried forward.
* Determination of definite polyps in the study eye at screening.
† Determination of absent or questionable polyps in the study eye at screening.
BCVA = best-corrected visual acuity; CRT = central retinal thickness; PCV = polypoidal choroidal vasculopathy; SEM = standard error of the mean
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studies (Figure 4). Mean (SEM) change in CRT from 
baseline at week 16, 8 weeks after the last abicipar 
injection and 4 weeks after the last ranibizumab in-
jection, was −187.3 (46.1) μm, −196.5 (39.3) μm, and 
−230.4 (26.5) μm in the BAMBOO study and −106.5 
(40.6) μm, −112.8 (53.7) μm, and −124.4 (22.1) μm in 
the CYPRESS study in the abicipar 1 mg, abicipar 2 
mg, and ranibizumab arms, respectively (Figure 4). 
At week 20, 12 weeks after the last abicipar injec-
tion and 4 weeks after the last ranibizumab injection, 
mean (SEM) change from baseline in CRT was −139.4 
(35.0) μm, −194.9 (34.6) μm, and −250.6 (22.7) μm in 
the BAMBOO study and −78.2 (33.1) μm, −90.3 (56.4) 
μm, and −110.4 (20.5) in the CYPRESS study in the 
abicipar 1 mg, abicipar 2 mg, and ranibizumab arms, 
respectively (Figure 4).
Subgroup Analysis by Presence/Absence of PCV
ICGA in the BAMBOO study demonstrated the 
presence of PCV in 14 of 25 patients (56%). Subgroup 
analysis of efficacy endpoints in the BAMBOO study 
by the presence or absence of PCV showed that abici-
par effectively improved BCVA and CRT in patients 
with PCV, as well as in patients without PCV (Table 
2). Mean change from baseline in BCVA at week 16 
was +6.0 letters, +9.8 letters, and +12.3 letters for 
patients with PCV and +9.6 letters, +7.5 letters, and 
+25.0 letters for patients without PCV in the abicipar 
1 mg, abicipar 2 mg, and ranibizumab arms, respec-
tively. Mean change from baseline in CRT at week 
16 was −268.6 μm, −191.2 μm, and −253.7 μm for 
patients with PCV and −106.0 μm, −204.5 μm, and 
−195.5 μm for patients without PCV in the abicipar 
1 mg, abicipar 2 mg, and ranibizumab arms, respec-
tively.
Case Studies
Effects of abicipar treatment in two patients are il-
lustrated in Figures 5 and 6. Figure 5 shows visual and 
anatomic outcomes in a 91-year-old Caucasian female 
who was treated with abicipar 2 mg at day 1, week 
4, and week 8 in the CYPRESS study. At baseline, 
BCVA in the study eye was 56 letters (approximately 
20/80 Snellen equivalent). One week after the first in-
travitreal injection of abicipar, CRT was reduced and 
BCVA had improved by 17 letters. BCVA of 73 letters 
(approximately 20/32 Snellen equivalent) or better 
was sustained through week 20.
Visual and anatomic outcomes in a 77-year-old 
Japanese male who was treated with abicipar 2 mg in 
the BAMBOO study are shown in Figure 6. Screening 
ICGA demonstrated a PCV component of the lesion 
TABLE 3
Adverse Events Reported in Two or More Patients Across Studies, n (%)
BAMBOO (Japan) CYPRESS (United States)
Adverse Event Abicipar 1 mg 
(n = 10)
Abicipar 2 mg 
(n = 10)
RAN 0.5 mg  
(n = 5)
Abicipar 1 mg 
(n = 10)
Abicipar 2 mg 
(n = 10)
RAN 0.5 mg 
(n = 5)
Conjunctival 
hemorrhage
4 (40) 0 (0) 0 (0) 0 (0) 0 (0) 1 (20)
Dry eye 1 (10) 0 (0) 0 (0) 1 (10) 1 (10) 0 (0)
Cataract 1 (10) 0 (0) 1 (20) 0 (0) 0 (0) 0 (0)
Eye pain 0 (0) 0 (0) 0 (0) 0 (0) 1 (10) 1 (20)
Foreign body 
sensation in eyes
0 (0) 1 (10) 1 (20) 0 (0) 0 (0) 0 (0)
Intraocular pressure 
increased
0 (0) 0 (0) 2 (40) 0 (0) 0 (0) 0 (0)
Iritis 1 (10) 1 (10) 0 (0) 0 (0) 0 (0) 0 (0)
Oedema peripheral 0 (0) 0 (0) 0 (0) 0 (0) 1 (10) 1 (20)
Pneumonia 0 (0) 0 (0) 1 (20) 0 (0) 1 (10) 0 (0)
Vitreous floaters 1 (10) 1 (10) 0 (0) 0 (0) 0 (0) 0 (0)
Vitreous opacities 1 (10) 1 (10) 0 (0) 0 (0) 0 (0) 0 (0)
Vitritis 1 (10) 0 (0) 0 (0) 0 (0) 1 (10) 0 (0)
RAN = ranibizumab
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in the study eye. At baseline, BCVA was 41 letters 
(approximately 20/160 Snellen equivalent). Abicipar 
treatment was administered at day 1, week 4, and 
week 8. By week 12, CRT was reduced and BCVA had 
improved by 20 letters. These improvements persist-
ed through week 20, 12 weeks after the last abicipar 
injection. At week 20, BCVA was 63 letters (approxi-
mately 20/50).
Safety Outcomes
The overall incidence of AEs was eight of 10 
(80%), four of 10 (40%), and five of five (100%) in 
the BAMBOO study and five of 10 (50%), six of 10 
(60%), and two of five (40%) in the CYPRESS study 
in the abicipar 1 mg, abicipar 2 mg, and ranibizumab 
arms, respectively. The most common AE was con-
junctival hemorrhage (Table 3), which was associ-
ated with the injection procedure. All AEs that were 
considered possibly related to treatment were ocu-
lar, and none were serious. AEs of intraocular in-
flammation were reported in the abicipar arms; each 
of these AEs is listed in Table 4. These AEs were 
generally mild to moderate in severity, and all re-
solved with no treatment or with topical, intravit-
real, or oral corticosteroid therapy. None of the AEs 
of intraocular inflammation were associated with 
a sustained loss of vision (Table 4). No AEs of in-
traocular inflammation were reported in the ranibi-
zumab arms. Across the BAMBOO and CYPRESS 
studies, uveitis or vitritis was reported in three of 40 
abicipar-treated patients compared with zero of 10 
ranibizumab-treated patients.
All patients in the BAMBOO study (25 of 25 
[100%]) demonstrated stable vision throughout the 
study. In the CYPRESS study, 22 of 25 (88%) patients 
had stable vision at all scheduled study visits. With 
respect to patients in the CYPRESS study who did not 
achieve stable vision, one patient in the abicipar 2 mg 
arm had a 16-letter loss in BCVA from baseline on 
day 8 because of treatment-related vitritis; the vitri-
tis resolved and the patient subsequently achieved an 
8-letter BCVA gain from baseline. In addition, at week 
20, one patient in each abicipar treatment arm had a 
22- or 30-letter loss in BCVA from baseline because of 
an AE unrelated to treatment (progression of RPE at-
rophy or central retinal vein occlusion, respectively).
There were no Antiplatelet Trialists’ Collabora-
tion (APTC) arterial thromboembolic events (ATEs) 
reported in the abicipar treatment arms of either 
BAMBOO or CYPRESS. In the ranibizumab arm in 
the BAMBOO study, however, there was an APTC 
ATE report of embolic stroke. There was also one re-
port of increased blood pressure in the ranibizumab 
arm of the BAMBOO study. There were no reports of 
proteinuria, hemorrhagic events, or delayed wound-
healing.
DISCUSSION
nAMD is characterized by a sudden vision loss, 
and anti-VEGF agents such as ranibizumab have 
TABLE 4
Visual Outcomes After Intraocular Inflammation AEs
Intraocular 
Inflammation 
Adverse Event 
Preferred Term
Study Treatment Arm Baseline BCVA 
(Letters)
Change From 
Baseline BCVA 
After AE (Letters)
BCVA Change 
From Baseline 
at Study Exit 
(Letters)
Anterior chamber 
inflammation
BAMBOO Abicipar 1 mg 46 +16 +16
Iritis* BAMBOO Abicipar 1 mg 24 +21 +21
Vitritis* BAMBOO Abicipar 1 mg 24 +21 +21
Vitreous opacities BAMBOO Abicipar 1 mg 59   +1   +8
Iritis BAMBOO Abicipar 2 mg 51     0   +4
Vitreous opacities BAMBOO Abicipar 2 mg 73   +8 +12
Iridocyclitis CYPRESS Abicipar 1 mg 66 –20   +2
Uveitis CYPRESS Abicipar 2 mg 73 –38   –2
Vitritis CYPRESS Abicipar 2 mg 42 –18   +8
* One patient in the abicipar 1 mg arm of the BAMBOO study had reports of both iritis and vitritis in the study eye.
AE = adverse event; BCVA = best-corrected visual acuity
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changed clinical practice for the treatment of this dis-
ease.1 In registration studies of anti-VEGF treatment 
in nAMD,3,4,19 vision was improved or stabilized in 
the majority of patients, and the effects on vision 
were associated with significantly improved vision-
related quality-of-life outcomes.20,21 Consequently, 
intravitreal injections of anti-VEGF agents have be-
come the foundation of therapy for nAMD.1 How-
ever, in order to maintain optimal efficacy, frequent 
intravitreal injections are required. In clinical stud-
ies, monthly injections of anti-VEGF therapies have 
provided the best efficacy outcomes.22 Thus there 
is an unmet medical need for a therapy that main-
tains maximal efficacy while requiring less frequent 
injections. Such a therapy would potentially remove 
a significant treatment burden on patients and their 
health care providers, and also decrease the risk of 
complications associated with intravitreal injections 
such as endophthalmitis, retinal detachment, and el-
evated intraocular pressure. The BAMBOO and CY-
PRESS studies evaluated abicipar safety and efficacy 
in treatment-naïve patients with nAMD. The studies 
demonstrated comparable abicipar safety and a dura-
tion of abicipar efficacy of up to 12 weeks after the 
last dose in both Japanese and non-Japanese patients 
with nAMD. The results of the BAMBOO study fur-
ther suggest that abicipar is effective in treating Japa-
nese patients with PCV.
Patients in the abicipar treatment arms of the BAM-
BOO and CYPRESS studies received abicipar 1 mg or 
2 mg. These abicipar doses were the same as those 
evaluated in stage 3 of the phase 2 REACH study. 
Across all three studies, abicipar 2 mg demonstrated a 
greater, more consistent treatment effect than abicipar 
1 mg, supporting the use of abicipar 2 mg in ongoing 
phase 3 trials of abicipar for treatment of nAMD (clin-
icaltrials.gov NCT02462486, NCT02462928). The 
BAMBOO and CYPRESS data suggest that abicipar 
effects on BCVA are durable and maintained at least 
12 weeks after three monthly injections, confirming 
previous results in the REACH stage 3 study. Overall, 
the phase 2 data suggest that abicipar could provide 
an extended duration of effect and efficacy similar to 
that demonstrated by ranibizumab in its pivotal stud-
ies, but with reduced burden of visits for patients and 
health care providers.
At week 16, 8 weeks after the last abicipar injec-
tion, abicipar 2 mg provided mean gains in BCVA of 
+8.9 and +10.1 letters in the BAMBOO and CYPRESS 
studies, respectively. These effects are consistent 
with those observed in REACH stage 3, where abici-
par 2 mg achieved a mean gain in BCVA of 8.2 letters 
at week 16.16 In addition, overall gains in these three 
studies are consistent with BCVA improvements at 
week 16 after monthly injections of ranibizumab 0.5 
mg in the MARINA and ANCHOR registration trials 
of ranibizumab for treatment of nAMD (+9.9 letters in 
ANCHOR3 and approximately +6.1 letters in MARI-
NA (estimation from digitization using Engauge Digi-
tizer software [available at: http://engauge-digitizer.
soft112.com] of MARINA study data presented in Fig-
ure 2A of Rosenfeld et al.4) Evaluation of response to 
ranibizumab in the BAMBOO and CYPRESS studies 
indicates that patients (five in each study) respond-
ed unexpectedly well to ranibizumab, with week 16 
mean BCVA gains of +17.4 letters and +15.2 letters, 
respectively. The reason for this response, which is 
almost double that reported in ANCHOR, MARINA, 
and REACH stage 3, is difficult to understand. The 
most likely explanation is the small number of pa-
tients randomized to the active control arm (ie, by 
randomization chance these arms included a high 
percentage of patients who were highly responsive to 
ranibizumab).
With respect to vision stabilization, abicipar stabi-
lized vision (no loss in BCVA ≥ 15 letters) in almost 
all patients treated with abicipar in the BAMBOO and 
CYPRESS studies. These data are also consistent with 
those reported in the REACH stage 3 study in which 
all patients treated with abicipar at either dose (1 or 2 
mg) achieved stable vision.16
Abicipar induced similar improvements in ana-
tomical outcomes in BAMBOO and CYPRESS, high-
lighting the comparability of the Japanese and United 
States study populations in their CRT response to 
abicipar. The improvements were observed in each 
treatment arm at all follow-up visits for both studies. 
Since the last dose of abicipar was administered at 
week 8, maintenance of effect in anatomical outcomes 
reflects an extended duration of action of abicipar. 
Mean reduction in CRT from baseline was 187.3 μm, 
196.5 μm, and 230.4 μm in the BAMBOO study and 
106.5 μm, 112.8 μm, and 124.4 μm in the CYPRESS 
study at week 16, and 139.4 μm, 194.9 μm, and 250.6 
μm in the BAMBOO study and 78.2 μm, 90.3 μm, 
and 110.4 μm in the CYPRESS study at week 20, in 
the abicipar 1 mg, abicipar 2 mg, and ranibizumab 
arms, respectively. The CRT changes observed in the 
BAMBOO and CYPRESS studies are similar to those 
in the REACH stage 3 study, in which the mean CRT 
reductions from baseline were 161 μm, 111 μm, and 
127 μm at week 16 and 147 μm, 102 μm, and 125 μm 
at week 20 in the abicipar 1 mg, abicipar 2 mg, and 
ranibizumab 0.5 mg arms, respectively.16 These data 
support comparable effects of abicipar on anatomical 
endpoints in Japanese and non-Japanese patients and 
also provide evidence of a long duration of action of 
abicipar not only on functional endpoints (BCVA) as 
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described above, but also on retinal anatomy (CRT), 
with effects that can be observed at least 12 weeks 
after the last abicipar administration.
The effects of anti-VEGF treatment in patients 
with nAMD may be influenced by the subtype of 
nAMD.23,24 PCV is a distinct form of neovascular 
AMD that is characterized by a network of branch-
ing choroidal vessels with terminal, polyp-like dila-
tions that can be visualized on ICGA. It is frequently 
associated with serosanguineous detachments of the 
RPE. PCV and typical nAMD differ in epidemiologi-
cal and clinical characteristics, natural history, and 
treatment outcomes.9 It has been suggested that the 
neovascular lesions in typical AMD and PCV may 
respond differently to anti-VEGF therapy because 
of differences in the mechanisms underlying the 
neovascularization.25 Although ranibizumab, beva-
cizumab, and aflibercept have all demonstrated ef-
ficacy in improving vision, decreasing foveal thick-
ness, and causing polyp regression in patients with 
PCV,26-28 ranibizumab therapy may be more effective 
in eyes with typical nAMD than in eyes with PCV.8 
In the BAMBOO study, abicipar had beneficial ef-
fects on BCVA and CRT in both patients with PCV 
and patients with typical nAMD.
The safety profile of abicipar demonstrated in the 
BAMBOO and CYPRESS studies was acceptable. 
There were no AEs potentially related to systemic 
VEGF inhibition in the abicipar treatment arms. All 
treatment-related AEs in the abicipar arms were oc-
ular, and none were serious. The most common AE 
was conjunctival hemorrhage associated with the in-
jection procedure.
The BAMBOO and CYPRESS studies included 
treatment-naïve patients to allow a more robust 
evaluation of the treatment effects of abicipar and to 
prevent confounding effects from any previous treat-
ment. Study strengths included the use of ICGA and 
subgroup analysis based on the presence or absence 
of PCV in the Japanese patient population. Study 
limitations included the small sample sizes and the 
6-month study duration. A sustained duration of ef-
fect of abicipar relative to ranibizumab was inferred 
from the efficacy demonstrated by abicipar at 8 and 
12 weeks after the last of three monthly injections. We 
acknowledge that a study design that included a treat-
ment arm with three monthly ranibizumab injections, 
perhaps followed by a treat-and-extend option, would 
have allowed a more direct comparison of the dura-
tion of treatment effects of abicipar and ranibizumab. 
However, because this study was conducted to fulfil 
regulatory agency requirements, monthly administra-
tion of ranibizumab per its approved drug labelling 
was required. The effects of extended treatment with 
abicipar 2 mg at 8-week or 12-week intervals are un-
der investigation in ongoing phase 3 studies.
In summary, abicipar performed similarly in Jap-
anese and non-Japanese patients in the BAMBOO 
and CYPRESS studies, despite the presence of PCV 
in more than half of the Japanese patient population. 
Functional improvements, anatomic effects, and 
safety were comparable between abicipar 1 mg and 
2 mg treatment arms in each study. Improvements 
in BCVA and CRT with abicipar were sustained 
through week 20, 12 weeks after the last abicipar 
injection, demonstrating a long duration of abicipar 
effects. Improvements in BCVA and CRT were simi-
lar in PCV and non-PCV Japanese patients receiving 
abicipar 2 mg. Overall, the BAMBOO and CYPRESS 
data on abicipar confirm those from REACH stage 3. 
The data indicate that abicipar could achieve func-
tional and anatomical improvements in nAMD, but 
with a reduced number of injections and dosing in-
tervals of 8 weeks or 12 weeks, consistent with great-
er duration of action. The results of the phase 2 stud-
ies support further clinical development of abicipar 
2 mg for treatment of nAMD. 
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